Top

Published in:

01-03-2008 | ORIGINAL PAPER

Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment

Authors: Raisuke Iijima, MD, Gjin Ndrepepa, MD, Julinda Mehilli, MD, Franz-Josef Neumann, MD, Stefanie Schulz, MD, Jurriën ten Berg, MD, Olga Bruskina, MD, Franz Dotzer, MD, Josef Dirschinger, MD, Peter B. Berger, MD, Albert Schömig, MD, Adnan Kastrati, MD

Published in: Clinical Research in Cardiology | Issue 3/2008

Abstract

Objective

We investigated how does troponin level (TnT) affect the benefit achieved by abciximab in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with a high loading dose of clopidogrel.

Methods

The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT 2) trial included 2,022 patients with non-ST elevation ACS undergoing PCI who were randomized to abciximab or placebo after pretreatment with 600 mg of clopidogrel. The patients were divided into groups with elevated TnT level (n = 1,049) and no elevated TnT level (n = 973). The primary end point of the trial was the composite of death, myocardial infarction and urgent reintervention at 30 days.

Results

In patients with elevated TnT level the incidence of the primary end point was 13.1% in the abciximab group Vs. 18.3% in the placebo group [relative risk (RR): 0.70; 95% confidence interval (CI), 0.52–0.95, P = 0.02]. The combined incidence of death or myocardial infarction was 12.9% in the abciximab group vs. 17.9% in the placebo group (RR: 0.71; 95% CI, 0.52–0.96, P = 0.03). In contrast, the incidence of the primary end point in patients with no elevated TnT level was identical in both treatment groups (4.6%). The risk of bleeding was not related to TnT level.

Conclusions

Baseline troponin level affects the benefit of abciximab in patients with ACS undergoing PCI after pretreatment with a high loading dose of clopidogrel. Abciximab reduces the risk of ischemic events only in patients with ACS and elevated troponin level.

Alpert JS, Thygesen K, Antman E, Bassand JP (2000) Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:959–969PubMedCrossRef

Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reimann JD, Braunwald E (1999) Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 33:634–639PubMedCrossRef

Bhatt DL, Topol EJ (2000) Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 284:1549–1558PubMedCrossRef

Boden WE, O’Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, Wexler LF, Kleiger RE, Pepine CJ, Ferry DR, Chow BK, Lavori PW (1998) Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 338:1785–1792PubMedCrossRef

Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359:189–198PubMedCrossRef

Braunwald E (2003) Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction. Circulation 108:III28–III37PubMedCrossRef

Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr, American College of Cardiology, American Heart Association (2002) Committee on the management of patients with unstable angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 40:1366–1374PubMedCrossRef

Burke AP, Farb A, Malcom GT, Liang Y, Smialek JE, Virmani R (1999) Plaque rupture and sudden death related to exertion in men with coronary artery disease. JAMA 281:921–926PubMedCrossRef

Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E, TACTICS (Treat Angina with Aggrastat, Determine Cost of Therapy with an Invasive or Conservative Strategy)—Thrombolysis in Myocardial Infarction 18 Investigators (2001) Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344:1879–1887PubMedCrossRef

10.

Dokainish H, Pillai M, Murphy SA, DiBattiste PM, Schweiger MJ, Lotfi A, Morrow DA, Cannon CP, Braunwald E, Lakkis N (2005) Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol 45:19–24PubMedCrossRef

11.

Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, Wheatley DJ, Pocock SJ et al (2002) Randomized intervention trial of unstable angina investigators interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized intervention trial of unstable angina. Lancet 360:743–751PubMedCrossRef

12.

FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators (1999) Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 354:708–715CrossRef

13.

Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 326:310–318PubMedCrossRef

14.

Gluckman TJ, Sachdev M, Schulman SP, Blumenthal RS (2005) A simplified approach to the management of non-ST-segment elevation acute coronary syndromes. JAMA 293:349–357PubMedCrossRef

15.

Gurbel PA, Bliden KP, Hayes KM, Tantry U (2004) Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2:535–545PubMedCrossRef

16.

Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US (2005) Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111:1153–1159PubMedCrossRef

17.

Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, Rutsch W, Berger J, Kootstra J, Simoons ML (1999) Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 340:1623–1629PubMedCrossRef

18.

Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD (1999) Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 354:1757–1762PubMedCrossRef

19.

Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML (1999) Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 100:1509–1514PubMed

20.

Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA (2001) The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 38:478–485PubMedCrossRef

21.

Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Buttner HJ, Neumann FJ (2005) Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111:2560–2564PubMedCrossRef

22.

Kandzari DE, Berger PB, Kastrati A, Steinhubl SR, Mehilli J, Dotzer F, Ten Berg JM, Neumann FJ, Bollwein H, Dirschinger J, Schömig A, ISAR-REACT Study Investigators (2004) Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 44:2133–2136PubMedCrossRef

23.

Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schuhlen H, Dirschinger J, Berger PB, Schömig A, Intracoronary Stenting, Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295:1531–1538PubMedCrossRef

24.

Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A, Intracoronary Stenting, Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators (2004) A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350:232–238PubMedCrossRef

25.

Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schömig A (2004) Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 110:1916–1919PubMedCrossRef

26.

Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853–863PubMedCrossRef

27.

Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A, Intracoronary Stenting, Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators (2004) Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110:3627–3635PubMedCrossRef

28.

Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH, Hille DA, DeLucca PT, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E, TACTICS-TIMI 18 Investigators (2001) Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 286:2405–2412PubMedCrossRef

29.

Muller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schömig A, Gawaz M (2001) Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85:92–93PubMedCrossRef

30.

Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP, Schmitt C, Seyfarth M, Dirschinger J, Schömig A (2003) Evaluation of prolonged antithrombotic pretreatment (“cooling-off” strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 290:1593–1599PubMedCrossRef

31.

Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Van De Werf F, Pfisterer M, Hasselblad V, Califf RM, Topol EJ (2001) Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the paragon-B troponin T substudy. Circulation 103:2891–2896PubMed

32.

Newby LK, Roe MT, Chen AY, Ohman EM, Christenson RH, Pollack CV Jr, Hoekstra JW, Peacock WF, Harrington RA, Jesse RL, Gibler WB, Peterson ED, CRUSADE Investigators (2006) Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. J Am Coll Cardiol 47:312–318PubMedCrossRef

33.

Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O’Hanesian MA, Wagner GS, Kleiman NS, Harrell FE Jr, Califf RM, Topol EJ (1996) Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 335:1333–1341PubMedCrossRef

34.

Pache J, Kastrati A, Mehilli J, Gawaz M, Neumann FJ, Seyfarth M, Hall D, Braun S, Dirschinger J, Schömig A (2002) Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen. Catheter Cardiovasc Interv 55:436–441PubMedCrossRef

35.

Periinterventional Abciximab + Heparin Vs. Bivalirudin in Acute Coronary Syndrome (ISAR-REACT-4) (2007) http://www.clinicaltrial.gov/. Accessed 1 May 2007

36.

Schömig A, Schmitt C, Dibra A, Mehilli J, Volmer C, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Berger PB, Kastrati A, Intracoronary Stenting, Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators (2005) One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J 26:1379–1384PubMedCrossRef

37.

Schulman SP (2004) Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes. JAMA 292:1875–1882PubMedCrossRef

38.

Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ, CREDO Investigators (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288:2411–2420PubMedCrossRef

39.

Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM, ACUITY Investigators (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203–2216PubMedCrossRef

40.

TIMI IIIB Trial Investigators (1994) Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Circulation 89:1545–1556

41.

TIMI Study Group (2007) Definitions used in TIMI trials. http://www.timi.org. Accessed 7 January 2007

42.

Topol EJ, Yadav JS (2000) Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101:570–580PubMed

43.

von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A (2005) Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) trial. Circulation 112:2946–2950

44.

Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E (2000) Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 356:9–16PubMedCrossRef

45.

Wong GC, Morrow DA, Murphy S, Kraimer N, Pai R, James D, Robertson DH, Demopoulos LA, DiBattiste P, Cannon CP, Gibson CM (2002) Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 106:202–207PubMedCrossRef

46.

Yusuf S, Mehta SR, Zhao F, Gersh BJ, Commerford PJ, Blumenthal M, Budaj A, Wittlinger T, Fox KA, Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators (2003) Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107:966–972PubMedCrossRef

47.

Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502PubMedCrossRef

Title: Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment
Authors: Raisuke Iijima, MD
Gjin Ndrepepa, MD
Julinda Mehilli, MD
Franz-Josef Neumann, MD
Stefanie Schulz, MD
Jurriën ten Berg, MD
Olga Bruskina, MD
Franz Dotzer, MD
Josef Dirschinger, MD
Peter B. Berger, MD
Albert Schömig, MD
Adnan Kastrati, MD
Publication date: 01-03-2008
Publisher: Steinkopff-Verlag
Published in: Clinical Research in Cardiology / Issue 3/2008
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-007-0603-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2008

The case for statin therapy in chronic heart failure

Medizinische Leitlinie zur Behandlung von Erwachsenen mit angeborenen Herzfehlern (EMAH)

Combined cardiac surgical procedures in octogenarians: operative outcome

Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany

Replacement of valved right ventricular to pulmonary artery conduits: an observational study with focus on right ventricular geometry

Transcatheter recanalization of acutely occluded modified systemic to pulmonary artery shunts in infancy